Beta Bionics officer proposes $6.51K share sale
Merrill Lynch is named as broker, and NASDAQ as the exchange for the proposed common-share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Beta Bionics, Inc. officer Stephen Feider reported a proposed sale of 382 common shares through Merrill Lynch, with an approximate sale date of November 5, 2026. The shares have an aggregate market value of $6,508. Stephen Feider also reported sales of 6,675 common shares during the prior three months, on September 2, 2026, with an aggregate value of $129,595.13.
Key Figures
Key Terms
Rule 144 regulatory
stock options technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.